October, 2019 | PharmaShots

Janssen’s Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma

October 31, 2019October 31, 2019Tuba Khan

Shots: The approval is based on P-III MAIA study assessing Darzalex + lenalidomide + dexamethasone (Rd) vs Rd as monothx. in 737 patients [Read More...]

Roche Signs a Development and Commercialization Agreement with Dicerna for its DCR-HBVS to Treat Chronic Hepatitis B Virus Infection

October 31, 2019October 31, 2019Tuba Khan

Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of [Read More...]

AliveCor and Huami Collaborate to Bring the Next Generation ECG Wearables Devices

October 31, 2019October 31, 2019Tuba Khan

Shots: The companies together formed a multi-faceted global strategic alliance which combines the technologies of both the companies to deliver a new generation [Read More...]

Johnson & Johnson Vision Launches TECNIS Eyhance Monofocal Intraocular Lens for Post Cataract Surgery Patients in India

October 31, 2019October 31, 2019Tuba Khan

Shots: J&J Vision launches TECNIS Eyhance monofocal IOL to provide the advance solution for patients who have undergone cataract removal surgery The launch [Read More...]

Shreis Scalene’s Cytotron Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

October 31, 2019November 14, 2019Tuba Khan

Shots: The US FDA’s Center for Devices and Radiological Health has granted breakthrough device designation for Shreis’ Cytotron, invented by Dr. Rajah Vijay [Read More...]

Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

October 31, 2019October 31, 2019Tuba Khan

Shots: Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and [Read More...]

Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

Novartis Reports FDA’s Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101 (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy Type 2

October 30, 2019November 4, 2019Tuba Khan

Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia [Read More...]

Month
October 2019

Janssen’s Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma

Roche Signs a Development and Commercialization Agreement with Dicerna for its DCR-HBVS to Treat Chronic Hepatitis B Virus Infection

AliveCor and Huami Collaborate to Bring the Next Generation ECG Wearables Devices

Johnson & Johnson Vision Launches TECNIS Eyhance Monofocal Intraocular Lens for Post Cataract Surgery Patients in India

Shreis Scalene’s Cytotron Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for Multiple Sclerosis

LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

Novartis Reports FDA’s Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101 (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy Type 2